Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Pharmacol Ther ; 105(1): 168-176, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-29885208

RESUMO

Merck & Co, Inc (Kenilworth, NJ) is investing in approaches to enrich clinical trial data and augment decision making through use of digital health technologies, outpatient sampling, and real-time data access. As part of this strategy, a phase I study was conducted to explore a few technologies of interest. In this fixed-sequence two-period trial, 16 healthy subjects were administered 50-mg once-daily sitagliptin packaged in a bottle that electronically captured the date and time study medication was dispensed (period 1) and in a traditional pharmacy bottle (period 2). Dried blood spot samples were collected for sitagliptin concentration analysis on select study days, both in clinic and at home, with collection time recorded using an electronic diary in period 1 and by clinic staff in period 2. Study results demonstrated the feasibility and subject acceptance of collecting digital adherence data and outpatient dried blood spot samples in clinical trials and highlighted areas for future improvements.


Assuntos
Teste em Amostras de Sangue Seco/métodos , Desenvolvimento de Medicamentos/métodos , Hipoglicemiantes/sangue , Fosfato de Sitagliptina/sangue , Telemedicina/métodos , Adulto , Teste em Amostras de Sangue Seco/normas , Desenvolvimento de Medicamentos/normas , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Masculino , Pessoa de Meia-Idade , Fosfato de Sitagliptina/administração & dosagem , Manejo de Espécimes/métodos , Manejo de Espécimes/normas , Inquéritos e Questionários/normas , Telemedicina/normas , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA